Drug makers Valeant Pharmaceuticals International Inc., Actavis PLC and Mylan Inc. have all expressed interest in buying Pfizer Inc.'s branded generics business, but no active discussions are going on at this time, Reuters reported, citing three people close to the matter.

Pfizer is aware of each of the companies' interest but isn't yet ready to entertain a deal as it prepares the groundwork for a potential separation of the generics business, Reuters reported.

Full story at http://www.reuters.com/article/2014/01/14/us-pfizer-valeant-idUSBREA0D0CZ20140114

Write to copydesk@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Mylan NV Charts.
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Mylan NV Charts.